What HEMO BIOENGINEERING does

HEMO BIOENGINEERING LIMITED is a Singapore-based, privately-held medical device company founded in 2017 that develops and commercializes interventional devices for neurovascular and peripheral vascular diseases. The company was founded by Professor Jack Wang, former CEO of SGX Mainboard-listed Biosensors International Group and JW Medical Systems, and is headquartered in Singapore with R&D in the United States and manufacturing operations in China and Malaysia. As of the latest reporting, the company has 51-100 employees and has raised approximately US$138.5 million in venture funding across Series A through Series C rounds between 2017 and 2020.

The company's product portfolio spans three categories: mechanical thrombectomy devices (AsprAX Aspiration Catheter and CerebrAX Stent Retriever System, both CE MDR approved; Afentta Aspiration Catheter, China's first domestically-produced aspiration catheter system with NMPA approval); neuro access and dilation devices (EmerAX Access Catheter, FlexStar Balloon Guiding Catheter, Mountix Micro Catheter, FocuStar Neuro Balloon Catheter, Bonpass Intracranial Balloon Dilation Catheter); and peripheral vascular products (FocusLine PTA Balloon Dilation Catheter, Instalief hemorrhoid device). Proprietary catheter design elements include novel braiding techniques, ultra-soft and ultra-thin profiles, and larger inner lumen relative to peers at same outer diameter. Key regulatory milestones include NMPA approvals for multiple devices in China, CE MDR approvals in 2023, EN ISO 13485:2016 certification, and Class 10K Cleanroom certification.

The business model is B2B enterprise hardware sales, with products sold directly to hospitals, stroke centers, and neurointerventionalists and through international distribution partners across Europe, Asia, and the Middle East. The company also generates revenue through OEM manufacturing services for medical devices and a regulatory and market access partnership service that helps third-party medical device companies enter nine Southeast Asian markets. Pricing is negotiated enterprise-by-enterprise and not publicly disclosed. Distribution channels include direct hospital sales, international distribution partners across Europe, Asia, and the Middle East, and a Southeast Asia regulatory services network. The company maintains thought leadership through LinkedIn, educational stroke-awareness website content, and participation in medical conferences including CSA and TISC.

Name

HEMO BIOENGINEERING

Legal name

HEMO BIOENGINEERING LIMITED

Website

https://hemocorp.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

HEMO BIOENGINEERING is a Singapore-based medical device company that develops and commercializes CE MDR and NMPA approved interventional catheters for mechanical thrombectomy, neurovascular access, and peripheral vascular procedures, selling to hospitals and stroke centers across Asia, Europe, and the Middle East.

Ownership category

akta.pro rank

Product category

Neurovascular Interventional Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Interventional medical devices
• Neurovascular devices
• Mechanical thrombectomy
• Aspiration catheters
• Peripheral vascular catheters

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of neurovascular and peripheral vascular interventional medical devices including aspiration catheters, stent retrievers, access catheters, balloon dilation catheters, and micro catheters to hospitals and healthcare institutions.
2. OEM Services: Original equipment manufacturing services for medical devices.
3. Regulatory and Market Access Services: Regulatory and market access partnership strategic services for medical device companies desiring to venture into different markets in Southeast Asia. Services include product registration, license procurement, post-market compliance, importation, customs clearance, and distribution support.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

HEMO BIOENGINEERING develops, manufactures, and commercializes a portfolio of interventional medical devices for neurovascular and peripheral vascular diseases, including mechanical thrombectomy devices (aspiration catheters and stent retrievers), access and guiding catheters, neuro and peripheral balloon dilation catheters, and a hemorrhoid treatment device. The company sells these devices to hospitals, stroke centers, and neurointerventionalists, and provides OEM manufacturing and regulatory/market access partnership services for Southeast Asia.

Product overview

HEMO BIOENGINEERING is a medical device company developing innovative interventional medical devices for neurovascular and peripheral diseases. The product portfolio consists of three main categories: (1) Mechanical Thrombectomy Devices including AsprAX Aspiration Catheter, CerebrAX Stent Retriever System, and Afentta Aspiration Catheter for acute ischemic stroke treatment; (2) Neuro Access and Dilation Devices including EmerAX Access Catheter, FlexStar Balloon Guiding Catheter, Mountix Micro Catheter, FocuStar Neuro Dilation Catheter (Rx), and Bonpass Neuro Dilation Catheter (OTW) for neuro-interventional procedures; and (3) Peripheral Products including Instalief (hemorrhoid treatment device) and FocusLine PTA Balloon Dilation Catheter for peripheral vascular procedures. The company also provides OEM manufacturing services and regulatory/market access partnership services for medical device companies entering Southeast Asian markets.

Differentiator

Problem solved

Functional benefit

Brands

• FocusLine: PTA balloon dilation catheter product line for peripheral vascular interventions.
• Afentta
• FocuStar
• AsprAX
• CerebrAX
• EmerAX
• FlexStar
• Mountix
• Bonpass
• Instalief

Products and services

• AsprAX Aspiration Catheter CE MDR approved flagship aspiration catheter for mechanical thrombectomy treatment of acute ischemic stroke. Features large inner lumen for greater aspiration force, comprehensive sizes (0.035" to 0.088") and lengths (100cm to 158cm), soft distal tip with strong proximal end for enhanced navigability, superior pushability with kink prevention, and proprietary braiding technique.
• CerebrAX Stent Retriever System CE MDR approved self-expanding stent retriever for mechanical thrombectomy in acute ischemic stroke. Available in 3mm, 4mm, 5mm and 6mm diameters, with multiple radiopaque markers for visibility, strong nitinol alloy construction, and softer atraumatic stent design for vessel safety.
• Afentta Aspiration Catheter NMPA approved intracranial thrombectomy aspiration catheter developed by HEMO BIOENGINEERING (CHINA) LTD, China's first domestically-produced aspiration catheter system. Uses proprietary technologies for direct aspiration treatment of acute ischemic stroke with demonstrated shorter procedure times, higher recanalization rates, lower disability rates, and lower incidence of arterial dissection.
• EmerAX Access Catheter Intermediate access catheter for neuro-interventional procedures in treatment of acute ischemic stroke, intracranial atherosclerosis, and hemorrhagic stroke. Single lumen, braid- and coil-reinforced variable stiffness catheter with smooth transitioning, ultra-soft tip, good kink-resistance, trackability, and shape memory. Sizes range from 0.055" to 0.088" inner diameter and 80cm to 132cm effective length.
• FlexStar Balloon Guiding Catheter Balloon guiding catheter that effectively dissuades blood flow while exerting negative pressure aspiration or creating an arteriovenous short circuit to reverse direction of blood flow. Designed for neuro-interventional therapy applications.
• Mountix Micro Catheter Micro catheter with gradient design for effective transmission of push force and torque control to reach awkward positions in tortuous vasculature. Features smooth and seamless pushability with exclusive hydrophilic coating formula to reduce surface friction.
• FocuStar Neuro Dilation Catheter (Rx) Latest generation rapid-exchange neuro dilation catheter for treatment of intracranial stenosis. Features dual radiopaque markers for balloon location monitoring under X-ray, smooth surface coating for improved pushability, ultra-thin wall for flexibility and pressure-resistance, and short soft thin tip for navigating tortuous vessels.
• Bonpass Neuro Dilation Catheter (OTW) Over-the-wire intracranial balloon dilation catheter designed to lower pressure while effectively enhancing safety. Coaxial design improves tractability towards lesion with better performance through tortuous vessels, intended for treatment of intracranial stenosis.
• FocusLine PTA Balloon Dilation Catheter Proprietary, self-developed and self-manufactured percutaneous transluminal angioplasty (PTA) balloon dilation catheter for peripheral interventional procedures. Features inflatable balloon at tip used in minimally invasive catheterization procedures to enlarge narrowed vessel openings.
• Instalief Hemorrhoid Treatment Device Hand-held device providing effective physical relief of hemorrhoidal symptoms. Features a cooling balloon that directly applies pressure onto hemorrhoids to stem bleeding while low temperatures alleviate pain and discomfort.
• OEM Manufacturing Services for Medical Devices Original Equipment Manufacturing (OEM) services for medical devices, leveraging HEMO's Class 10K Cleanroom certified manufacturing operations across Singapore, Malaysia and China.
• Regulatory and Market Access Partnership Service Strategic regulatory and market access services for medical device companies seeking to enter Southeast Asian markets. Includes autonomous license holding, product registration, license procurement, post-market compliance, importation, customs clearance, and distribution support across Singapore, Vietnam, Thailand, Philippines, Indonesia, Malaysia, Hong Kong, Taiwan, and India.

Quantifiable outcome

• Achieved recanalization rates of 80-90% in clinical studies
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered core and strategic.

• Technology LicensorscoreTechnology or Integration · 1 January 2017In-licensed technologies for aspiration catheter and access catheter during early company formation.
• Key Opinion Leaders and Industry ExpertsstrategicStrategic or Co-development PartnerNetwork of key opinion leaders and industry experts supporting product development, clinical studies, and medical education.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic (via the legacy Covidien Solitaire stent retriever and neurovascular portfolio) competes head-to-head with HEMO's stent retrievers and access catheters in acute ischemic stroke and intracranial interventions.
• Stryker (Neurovascular): Stryker's Neurovascular division (Trevo stent retriever, acquired Concentric Medical) is a major incumbent in mechanical thrombectomy and intracranial access — the same product categories where HEMO positions CerebrAX and EmerAX.
• Johnson & Johnson (Cerenovus): Cerenovus (J&J MedTech) sells the Embotrap stent retriever and a broad neurovascular portfolio that overlaps directly with HEMO's mechanical thrombectomy and access device lines in major stroke centers.

Direct peers

• Penumbra: Penumbra is the global leader in aspiration-based mechanical thrombectomy (Penumbra System / RED reperfusion catheters), directly competing with HEMO's AsprAX and Afentta aspiration catheters in acute ischemic stroke treatment across hospitals and stroke centers.

Emerging players

• Acandis: Acandis develops stent retrievers and intracranial implant systems for mechanical thrombectomy and aneurysm treatment, competing in the same European neuro-interventional market where HEMO entered in 2023.
• Perflow Medical: Perflow Medical develops braided net-based stent retrievers and neurovascular devices, targeting the same acute ischemic stroke indication as HEMO's CerebrAX and AsprAX platforms.
• Rapid Medical: Rapid Medical develops stent retrievers (TigerTriever) and adjustable neurovascular devices focused on ischemic and hemorrhagic stroke — a niche, high-growth competitor in the same procedure categories HEMO targets.
• Phenox: Phenox is a Germany-based specialist in stent retrievers, flow diverters and intracranial access devices, selling into European and international stroke centers — overlapping with HEMO's CE MDR–targeted product portfolio.
• MicroPort Scientific (微创医疗): MicroPort's neurovascular subsidiary sells aspiration catheters and intracranial access devices in China and globally, making it one of the closest comparable Chinese neurovascular device players to HEMO BIOENGINEERING (CHINA) LTD.

Regional players

• Balt: Balt is a France-based neurovascular company with a broad portfolio of microcatheters, guide catheters and embolization devices used in European stroke and aneurysm centers, with overlapping technology to HEMO's access and micro-catheter range.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hemobioeng
• Facebookfacebook.com/profile.php

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HEMO BIOENGINEERING